Inflammation and antiangiogenesis in cancer

Area of Science:

• Immunology
• Oncology
• Molecular Biology

Background:

• The immune system plays a dual role in cancer, influencing angiogenesis via pro- and anti-angiogenic mediators.
• Both innate and adaptive immune cells are sources of these crucial mediators.
• Pre-clinical studies suggest synergy between anti-angiogenic strategies and immunotherapy.

Purpose of the Study:

• To review the angiogenic and anti-angiogenic properties of immune cell-derived molecules.
• To explore the potential pharmacological applications of these molecules as anti-angiogenic agents in cancer treatment.

Main Methods:

• Literature review of scientific articles focusing on immune cells, angiogenesis, and cancer.
• Analysis of pro- and anti-angiogenic mediators synthesized by various immune cell types.
• Examination of pre-clinical data on the interplay between anti-angiogenic molecules and immunotherapy.

Main Results:

• Immune cells, including macrophages, granulocytes, mast cells, dendritic cells, natural killer cells, platelets, T cells, and B cells, produce diverse angiogenic factors.
• These immune cells also synthesize critical anti-angiogenic molecules.
• Evidence indicates a synergistic effect when anti-angiogenic agents are combined with immunotherapies in pre-clinical cancer models.

Conclusions:

• Immune cell-derived molecules possess significant angiogenic and anti-angiogenic potential.
• These properties offer promising avenues for developing novel pharmacological anti-angiogenic agents for cancer therapy.
• The findings support further investigation into immune-based strategies for enhancing cancer treatment outcomes.